BELLUS Health is developing drugs for rare diseases with an initial focus on kidney disorders. The Company's lead program is KIACTA™, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often rapidly leads to dialysis and death.
BELLUS Health is also developing Shigamabs™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli ("sHUS"). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamabs™ has recently completed a Phase II clinical trial.